Keyword Suggestions

Results
 
 
Account Login
 
Username
 
 
 
Password
 
 
 
 
 

Library Navigation

 
 

Browse Conferences

 
 
 
22 Results Found, Showing 1 - 22
Sort By:
View:
Filter By:
Date/Time
Conference
Keyword
My Content
Start Date/Time:
End Date/Time:
 
Go
 
Conference
 
Keywords:
Click here to clear this filter
 
 
Go
Show only the content that I own
 
 
February 5, 2010 - Friday
 
rating
100 - PARP Inhibitors in Breast and Ovarian Cancer 
Relevancy:
100.00% 
 
Date/Time:
February 5, 2010   8:00am - 8:30am
 
Length:
45 Slides  
 
Total Credits:
1.00 CE / 0.50 CME  
 
Speaker:
Lee S. Schwartzberg, MD, FACP (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
October 17, 2009 - Saturday
 
SA04 - Latest Targeted Therapies for Breast Cancer 
Relevancy:
13.45% 
 
Date/Time:
October 17, 2009   9:55am - 10:30am
 
Length:
31m 03s - 45 Slides  
 
Total Credits:
0.50 CME  
 
Speaker:
Ruth O'Regan, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA04 - Latest Targeted Therapies for Breast Cancer 
Relevancy:
13.45% 
 
Date/Time:
October 17, 2009   9:55am - 10:30am
 
Length:
31m 03s - 45 Slides  
 
Speaker:
Ruth O'Regan, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA05 - HspC90 as Emerging Therapy in HER2 + Breast Cancer 
Relevancy:
10.96% 
 
Date/Time:
October 17, 2009   10:45am - 11:20am
 
Length:
17m 21s - 57 Slides  
 
Total Credits:
0.50 CME  
 
Speaker:
Shanu Modi, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA05 - HspC90 as Emerging Therapy in HER2 + Breast Cancer 
Relevancy:
10.96% 
 
Date/Time:
October 17, 2009   10:45am - 11:20am
 
Length:
17m 21s - 57 Slides  
 
Speaker:
Shanu Modi, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA07 - mTor Pathways as a New Target in Endometrial and Ovarian Cancers 
Relevancy:
60.24% 
 
Date/Time:
October 17, 2009   1:00pm - 1:35pm
 
Length:
19m 47s - 26 Slides  
 
Total Credits:
0.50 CME  
 
Speaker:
Marcela Del Carmen, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA07 - mTor Pathways as a New Target in Endometrial and Ovarian Cancers 
Relevancy:
60.24% 
 
Date/Time:
October 17, 2009   1:00pm - 1:35pm
 
Length:
19m 47s - 26 Slides  
 
Speaker:
Marcela Del Carmen, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA08 - Using Targeted Agents (EGFR and VEGF Inhibitors) as Radiation Modifiers 
Relevancy:
23.09% 
 
Date/Time:
October 17, 2009   1:35pm - 2:10pm
 
Length:
26m 41s - 36 Slides  
 
Total Credits:
0.50 CME  
 
Speaker:
David B. Solit, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA08 - Using Targeted Agents (EGFR and VEGF Inhibitors) as Radiation Modifiers 
Relevancy:
23.09% 
 
Date/Time:
October 17, 2009   1:35pm - 2:10pm
 
Length:
26m 41s - 36 Slides  
 
Speaker:
David B. Solit, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA11 - The Future of Oncology - Drugs in the Pipeline 
Relevancy:
15.49% 
 
Date/Time:
October 17, 2009   3:35pm - 4:10pm
 
Length:
43m 03s - 31 Slides  
 
Total Credits:
0.50 CME  
 
Speaker:
Bruce A. Chabner, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA11 - The Future of Oncology - Drugs in the Pipeline 
Relevancy:
15.49% 
 
Date/Time:
October 17, 2009   3:35pm - 4:10pm
 
Length:
43m 03s - 31 Slides  
 
Speaker:
Bruce A. Chabner, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
September 25, 2009 - Friday
 
B202 - New Directions in the Treatment of 'Triple Negative' Breast Cancer 
Relevancy:
11.93% 
 
Date/Time:
September 25, 2009   9:25am - 9:55am
 
Length:
31m 46s - 41 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Lee S. Schwartzberg, MD, FACP (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
B203 - Update on Hormone Therapy for Early Stage Breast Cancer: What Treatment, What Duration? 
Relevancy:
11.91% 
 
Date/Time:
September 25, 2009   1:30pm - 2:00pm
 
Length:
28m 33s - 46 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Hope S. Rugo, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
GY203 - Debate: All Patients at High Risk for Ovarian Cancer Should Undergo Routine Screening 
Relevancy:
53.61% 
 
Date/Time:
September 25, 2009   1:30pm - 2:00pm
 
Length:
41m 26s - 51 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speakers:
Michael J. Birrer, MD, PhD (Speaker Disclosure)
 
Beth Y. Karlan, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
GY204 - Evidence-Based Management of Newly Diagnosed Ovarian Carcinoma 
Relevancy:
58.66% 
 
Date/Time:
September 25, 2009   2:05pm - 2:35pm
 
Length:
34m 08s - 62 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
J. Tate Thigpen, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
ON204 - GI Cancers: Top Ten Breakthroughs 2008-2009 - A Literature Review 
Relevancy:
13.41% 
 
Date/Time:
September 25, 2009   2:05pm - 2:35pm
 
Length:
27m 57s - 41 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Shannon B. Holloway (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
GY205 - Debate: Paclitaxel, When Given in Combination with Every-Three-Week Carboplatin for Newly Diagnosed Advanced Ovarian Carcinoma, Yields Superior Efficacy when Given in a Dose-Dense Weekly Schedule Rather than Once Every Three Weeks 
Relevancy:
92.74% 
 
Date/Time:
September 25, 2009   2:40pm - 3:10pm
 
Length:
30m 26s - 50 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speakers:
Harry J. Long, MD, FACP (Speaker Disclosure)
 
J. Tate Thigpen, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
GY206 - A Rational Approach to the Use of Systemic Therapy in Recurrent or Persistent Ovarian Carcinoma 
Relevancy:
48.56% 
 
Date/Time:
September 25, 2009   4:05pm - 4:35pm
 
Length:
36m 03s - 49 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Thomas Herzog, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
ON206 - Spirituality - What's New 
Relevancy:
10.66% 
 
Date/Time:
September 25, 2009   4:05pm - 4:35pm
 
Length:
32m 54s - 31 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
 
Format:
     
  Synched Audio / Slides
 

 
GY207 - Debate: Therapy for the Patient with Platinum-Resistant/Refractory Recurrent Ovarian Carcinoma Should be Selected Based on the Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay 
Relevancy:
36.63% 
 
Date/Time:
September 25, 2009   4:40pm - 5:10pm
 
Length:
25m 13s - 76 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speakers:
Michael J. Birrer, MD, PhD (Speaker Disclosure)
 
Bradley J. Monk, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
ON207 - Sexuality and Cancer 
Relevancy:
31.78% 
 
Date/Time:
September 25, 2009   4:40pm - 5:10pm
 
Length:
34m 31s - 36 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Kate Tierney, RN, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
September 26, 2009 - Saturday
 
SC307 - Management of Neuropathy 
Relevancy:
20.62% 
 
Date/Time:
September 26, 2009   4:05pm - 4:35pm
 
Length:
32m 30s - 44 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Judith A. Paice, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
22 Results Found, Showing 1 - 22